Nanotechnology, Nanomedicine, and the Kidney

Hauser, Péter; Chang, Hsiao-Min; Yanagawa, Norimoto; Hamon, Morgan

doi:10.3390/app11167187

Cited by 31 publications

(21 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Larger particles (d H > 100 nm) are readily picked up by the phagocytic cells and accumulated in the liver and the spleen [ 40 , 43 ], whereby particles of the > 200 nm size diameter show higher uptake rates by the spleen in comparison to the liver [ 44 , 45 ]. Very small nanoparticles (< 10–15 nm) are eliminated by the kidneys [ 46 , 47 ]. Generally, ultrasmall MNPs nanoparticles enter the blood vessels of the glomeruli in the nephrons and are eventually extracted in urine by the ureter and then by the urinary bladder.…”

Section: Intravenously Injected Mnpsmentioning

confidence: 99%

Pharmacokinetics of magnetic iron oxide nanoparticles for medical applications

Nowak-Jary

Machnicka

2022

J Nanobiotechnol

View full text Add to dashboard Cite

Magnetic iron oxide nanoparticles (MNPs) have been under intense investigation for at least the last five decades as they show enormous potential for many biomedical applications, such as biomolecule separation, MRI imaging and hyperthermia. Moreover, a large area of research on these nanostructures is concerned with their use as carriers of drugs, nucleic acids, peptides and other biologically active compounds, often leading to the development of targeted therapies. The uniqueness of MNPs is due to their nanometric size and unique magnetic properties. In addition, iron ions, which, along with oxygen, are a part of the MNPs, belong to the trace elements in the body. Therefore, after digesting MNPs in lysosomes, iron ions are incorporated into the natural circulation of this element in the body, which reduces the risk of excessive storage of nanoparticles. Still, one of the key issues for the therapeutic applications of magnetic nanoparticles is their pharmacokinetics which is reflected in the circulation time of MNPs in the bloodstream. These characteristics depend on many factors, such as the size and charge of MNPs, the nature of the polymers and any molecules attached to their surface, and other. Since the pharmacokinetics depends on the resultant of the physicochemical properties of nanoparticles, research should be carried out individually for all the nanostructures designed. Almost every year there are new reports on the results of studies on the pharmacokinetics of specific magnetic nanoparticles, thus it is very important to follow the achievements on this matter. This paper reviews the latest findings in this field. The mechanism of action of the mononuclear phagocytic system and the half-lives of a wide range of nanostructures are presented. Moreover, factors affecting clearance such as hydrodynamic and core size, core morphology and coatings molecules, surface charge and technical aspects have been described. Graphical Abstract

show abstract

Section: Intravenously Injected Mnpsmentioning

confidence: 99%

Pharmacokinetics of magnetic iron oxide nanoparticles for medical applications

Nowak-Jary

Machnicka

2022

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…The primary filtrate is transmitted through fenestrated capillaries into the Bowman’s capsule, which encloses the glomerulus and collects the filtrate, via the renal vasculature to the glomeruli. The filtrate is subsequently passed via the proximal and distal renal tubules, where nutrients, water, and ions are reabsorbed, and waste products are released ( Hauser et al, 2021 ).…”

Section: Kidney Targeted Nanoparticle Drug Delivery Systemmentioning

confidence: 99%

“…When constructing nanomedicine, the size, shape, and charge of nanoparticles must be considered, since these will determine whether they are cleared or accumulated by the kidneys. A positively charged nanomedicine, for example, may be able to filter through a negatively charged GBM and podocytes more efficiently than neutral or negatively charged substances ( Hauser et al, 2021 ). Interaction sites and probable uptake sites of NPs, which are extracted or employed to target the kidney.…”

Section: Kidney Targeted Nanoparticle Drug Delivery Systemmentioning

confidence: 99%

“…Pro-drug NPs can be triggered in proximal tubular cells lysosomes. After being delivered from the efferent arteriole to the peritubular network, NPs that are not selected for renal filtration can interact with the renal tubular compartment ( Hauser et al, 2021 ). Targeting was done in two ways in the drug delivery system, which are active and passive targeting.…”

Section: Kidney Targeted Nanoparticle Drug Delivery Systemmentioning

confidence: 99%

See 1 more Smart Citation

Role of Nanotechnology and Their Perspectives in the Treatment of Kidney Diseases

Merlin

2022

Front. Genet.

View full text Add to dashboard Cite

Nanoparticles (NPs) are differing in particle size, charge, shape, and compatibility of targeting ligands, which are linked to improved pharmacologic characteristics, targetability, and bioavailability. Researchers are now tasked with developing a solution for enhanced renal treatment that is free of side effects and delivers the medicine to the active spot. A growing number of nano-based medication delivery devices are being used to treat renal disorders. Kidney disease management and treatment are currently causing a substantial global burden. Renal problems are multistep processes involving the accumulation of a wide range of molecular and genetic alterations that have been related to a variety of kidney diseases. Renal filtration is a key channel for drug elimination in the kidney, as well as a burgeoning topic of nanomedicine. Although the use of nanotechnology in the treatment of renal illnesses is still in its early phases, it offers a lot of potentials. In this review, we summarized the properties of the kidney and characteristics of drug delivery systems, which affect a drug’s ability should focus on the kidney and highlight the possibilities, problems, and opportunities.

show abstract

“…On the other hand, intra-arterial injection of nanoparticles carries risks of increased nanoparticle binding to blood components and can potentially lead to thrombi or stenosis. Moreover, during the therapy, circulating nanoparticles may interact with the kidneys [49,50], leading to a worst-case renal tubule blockage. Accordingly, a prerequisite for the preparation of nanoparticles will be the maximum delineation of nanoparticle sizes that are safe for administration to animals and, subsequently, to humans.…”

Section: Discussionmentioning

confidence: 99%

Gold Nanoparticles Permit In Situ Absorbed Dose Evaluation in Boron Neutron Capture Therapy for Malignant Tumors

et al. 2021

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is an anticancer modality realized through 10B accumulation in tumor cells, neutron irradiation of the tumor, and decay of boron atoms with the release of alpha-particles and lithium nuclei that damage tumor cell DNA. As high-LET particle release takes place inside tumor cells absorbed dose calculations are difficult, since no essential extracellular energy is emitted. We placed gold nanoparticles inside tumor cells saturated with boron to more accurately measure the absorbed dose. T98G cells accumulated ~50 nm gold nanoparticles (AuNPs, 50 µg gold/mL) and boron-phenylalanine (BPA, 10, 20, 40 µg boron-10/mL), and were irradiated with a neutron flux of 3 × 108 cm−2s−1. Gamma-rays (411 keV) emitted by AuNPs in the cells were measured by a spectrometer and the absorbed dose was calculated using the formula D = (k × N × n)/m, where D was the absorbed dose (GyE), k—depth-related irradiation coefficient, N—number of activated gold atoms, n—boron concentration (ppm), and m—the mass of gold (g). Cell survival curves were fit to the linear-quadratic (LQ) model. We found no influence from the presence of the AuNPs on BNCT efficiency. Our approach will lead to further development of combined boron and high-Z element-containing compounds, and to further adaptation of isotope scanning for BNCT dosimetry.

show abstract

Nanotechnology, Nanomedicine, and the Kidney

Cited by 31 publications

References 96 publications

Pharmacokinetics of magnetic iron oxide nanoparticles for medical applications

Pharmacokinetics of magnetic iron oxide nanoparticles for medical applications

Role of Nanotechnology and Their Perspectives in the Treatment of Kidney Diseases

Gold Nanoparticles Permit In Situ Absorbed Dose Evaluation in Boron Neutron Capture Therapy for Malignant Tumors

Contact Info

Product

Resources

About